Clinical trial · Observational
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC)
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC): a Single Centre Feasibility Study
NCT05727319CI-TRIAL-00085634AIR-PANCcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to determine the feasibility of acquiring serial MRI images for longitudinal analysis in pancreatic ductal adenocarcinoma (PDAC) patients. The main question it aims to answer: Is it feasible to acquire baseline and repeat MR images in Radiotherapy treatment position?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Reproduciblity
- timeFrame
- 18 months
- description
- The proportion of patients who have successfully completed acquisition of a baseline and week 1 repeat scans
- measure
- Volumetric and functional feasibility
- timeFrame
- 18 months
- description
- The proportion of patients where volumetric and functional measurements are reproducible between baseline and repeat scans
- measure
- Region of interest quantifiability
- timeFrame
- 18 months
- description
- The proportion of patients where a region of interest can be created and quantified imaging parameters (e.g. ADC) can be extracted on baseline and repeat imaging
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed localised PDAC -as determined by the West of Scotland Hepato-Pancreatobiliary (HPB) MDT * Scheduled to undergo RT +/- chemotherapy * 18 years of age or older * Measurable disease on imaging * Able to give written informed consent * Patients willing and able to comply with the protocol for the duration of the study Exclusion Criteria: * Distant metastatic disease * Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating physician. * History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol * Major surgery within 28 days prior to trial entry * Any contraindication to MR * MRI unsafe implants, ferrous metal in the body, insufficient information on previous surgeries, MRI conditional implants where the conditions cannot be met (e.g. pacemakers).
References
Publications (0)
Data not yet available
No reference posted for this study.